Gileadex has reported its fourth consecutive quarter of positive results from a clinical trial involving a vaccine to treat the rare but deadly liver disease cirrhosis.
The company’s shares closed up 1 percent to $12.43 on Friday.
The stock has gained more than 30 percent in the past two months.
Gilead announced the results of a trial involving the hepatitis C vaccine last week.
The hepatitis C virus can lead to liver failure, but Gileady’s vaccine targets the liver rather than the pancreas.
Gileaderx also announced in March that it was working on a hepatitis C drug to treat people with other conditions.
“We continue to work with the FDA to identify the most effective and safe treatments for cirrhotic liver disease, including our hepatitis C vaccines, and to move forward with development and testing of these treatments,” Gileads Chief Executive Officer Michael E. Tamburro said in a statement on Friday morning.
“We are excited about the potential of this vaccine to reduce the risk of new liver cancers.”
Dr. Jonathan Wai, a hepatologist at the University of Colorado Medical Center, said that his research group’s results are not as promising as some other research in liver disease.
“They’re not the same as studies from other companies that have actually been looking at the effects of these vaccines,” Wai said.
“So, they’re not as conclusive as what we’d expect.”
“But they are the kind of things that, if I had to bet, the FDA would be looking at.
They are a promising tool, and if they can show that they’re doing something that has an impact on the disease process, then maybe they can move forward.”
Wai said that if the results are positive, Gileado could potentially move ahead with another phase two clinical trial of the vaccine in 2019.
“The thing that’s important to remember is that these are preliminary results, and it could take a year or two for the clinical trial to get going,” Wafai said, referring to the time between when a drug is approved and when a clinical study starts.
“That means that the safety and efficacy of the vaccines, if it’s really there, is really hard to judge.”
The drug is currently undergoing Phase 3 testing in two clinics in New Zealand and Australia.
Giles vaccines are manufactured by a company called Gileades, which has a clinical partner in the UK company Bristol-Myers Squibb.
Wai told Bloomberg that the company is still “focusing” on clinical trials.
“I think we’re still working through the phases of clinical trials, so I don’t think we’ll have any updates to share in the near future,” Waleys statement said.
The news comes as Gileaders Chief Executive officer Michael E Tamburello said the company expects to announce new clinical trials next month.
Gilligan’s is not the only drug company in the spotlight for failing to produce a hepatitis vaccine.
The FDA has issued a “red flag” warning for Johnson & Johnson, the pharmaceutical company that is a major investor in GileadaX, for failing “to ensure that the hepatitis A vaccine in its pipeline was clinically effective, safe and appropriate for human use.”
Gileads vaccine is currently awaiting FDA approval.